Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by 20c, Offers FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by 20c, Offers FY Guidance

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results

February 23, 2021 4:05 PM EST

DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2020 and provided financial guidance for 2021.

"In 2020, we made meaningful progress toward our goal to significantly grow and diversify 2022 revenues from products launched since 2019, highlighted by the strong execution of our U.S. launches of both Zepzelca and Xywav.  Despite the pandemic, we delivered important new treatment options for patients, ensured the well-being of employees and generated significant value for shareholders.  We meaningfully increased revenues, executed three product launches,... More